Apparently, global big pharmaceutical enterprises have been concentrated on issuing 2016 financial reports recently.
|
Company |
2016 revenue (USD 100 million) |
2015 revenue (USD 100 million) |
Growth rate |
|
J & J |
718.9 |
700.74 |
2.60% |
|
Pfizer |
528 |
475.7 |
11% |
|
Roche |
509.4 |
489.4 |
4% |
|
Novartis |
485.18 |
494.14 |
-2% |
|
MSD |
398.07 |
394.98 |
0.70% |
|
AbbVie |
256.38 |
228.59 |
12.20% |
|
AstraZeneca |
230.02 |
247.08 |
-6.90% |
|
Eli Lilly |
212.22 |
199 |
6% |
|
BMS |
194.27 |
165.6 |
17% |
|
Celgene |
111.85 |
91.6 |
20% |
|
Biogen |
111.49 |
107.64 |
6% |
( Source: E-Drug Manager E药经理人)

There seems to be no doubt that J & J was the leader in sales in 2016, although some pharmaceutical enterprises have not announced their 2016 performance. According to its 2016 financial report, J & J achieved USD 71.89 billion sales in 2016, which only grew by 2.6% compared to last year, but had exceeded the sum of 2016 sales of AbbVie, AstraZeneca and Eli Lilly in the absolute figure.
The top 3 giants in global sales among transnational pharmaceutical enterprises have been Pfizer, Roche and Novartis for a long time, with only positions among the top 3 differing. However, apparently, this pattern is being broken in recent years, and the kings used to be face much pressure. The sales of J & J which topped this time were nearly USD 20 billion more than that of Pfizer, the second place, showing the strong competitiveness.
The "explosion" of J & J came from the large grow...










(All Rights Reserved)